The objective of this investigation was to develop methods for the pharmaceutical analysis of a parenteral dosage form of gimantan, a new anti-Parkinson’s drug. The physicochemical properties of gimantan solution for injection have been investigated. Methods for the determination of the impurity content and the quantitative drug assay were developed based on thin-layer chromatography (TLC) and gas chromatography (GC), respectively. The drug was identified using TLC and GC simultaneously with the purity evaluation and quantitative determination of gimantan. The stability during storage has been studied. The quality standards for gimantan parenteral dosage form have been developed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
RF Pat. No. 1,825,499, “N-(2-adamantyl)hexamethyleneimine hydrochloride with anticataleptic activity” [in Russian], S. B. Seredenin, T. A. Voronina, N. I. Avdyunina, et al.,; Byull. Izobret., No. 4 (2010).
E. A. Val’dman, T. A. Voronina, and L. N. Nerobkova, Eksp. Klin. Farmakol., 4, 3 – 7 (1999).
E. A. Val’man, M. V. Elshanskaya, A. I. Sobolevskii, et al., Eksp. Klin. Farmakol., 1, 12 – 15 (2001).
E. A. Val’dman, T. A. Voronina, L. N. Aksenova, et al., Eksp. Klin. Farmakol., 5, 3 – 5 (2003).
G. N. Nezhinskaya, E. A. Val’dman, P. G. Nazarov, et al., Eksp. Klin. Farmakol., 2, 60 – 63 (2001).
E. A. Tsvetkova, M. Yu. Volkova, O. B. Stepanenko, et al., Khim.-farm. Zh., 35(2), 51 – 54 (2001).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 45, No. 8, pp. 49 – 52, August, 2011.
Rights and permissions
About this article
Cite this article
Sergeeva, M.S., Grushevskaya, L.N., Pyatin, B.M. et al. Pharmaceutical analysis and standardization of gimantan parenteral dosage form. Pharm Chem J 45, 499–502 (2011). https://doi.org/10.1007/s11094-011-0664-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-011-0664-1